Medtronic has received CE mark approval to expand the indications of its MiniMed 780G automated insulin delivery system. The clearance now includes people with type 2 diabetes and expands eligibility for children as young as two years old with type 1 diabetes, as well as use during pregnancy.
The MiniMed 780G is Medtronic’s most advanced AID system, delivering automatic insulin adjustments and corrections every five minutes for both basal and bolus needs. It features built-in meal detection technology and is paired with the Simplera Sync CGM.
Medtronic submitted clinical data from children aged 2–6, pregnant women, and people with insulin-requiring type 2 diabetes. The company said the approval reinforces its mission to broaden access to diabetes technology across diverse populations and life stages.
Follow MEDWIRE.AI for updates in diabetes technology.
